[HTML][HTML] Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao, J Li… - BMC medicine, 2022 - Springer
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
C Zhou, X Li, Q Wang, G Gao, Y Zhang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
Pyrotinib in patients with HER2-amplified advanced non–small cell lung cancer: A prospective, multicenter, single-arm trial
Z Song, D Lv, SQ Chen, J Huang, Y Li, S Ying… - Clinical Cancer …, 2022 - AACR
Purpose: In this study, we aimed to evaluate the efficacy and safety of pyrotinib, a pan-HER
inhibitor, in patients with HER2-amplified non–small cell lung cancer (NSCLC). Patients and …
inhibitor, in patients with HER2-amplified non–small cell lung cancer (NSCLC). Patients and …
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
SYM Liu, HY Tu, XW Wei, HH Yan, XR Dong, JW Cui… - Nature Medicine, 2023 - nature.com
To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC)
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in …
[HTML][HTML] Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Z Song, Y Li, S Chen, S Ying, S Xu, J Huang, D Wu… - BMC medicine, 2022 - Springer
Background There is currently a lack of effective treatments for non-small cell lung cancer
(NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and …
(NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and …
Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
G Gao, X Li, Q Wang, Y Zhang, J Chen, Y Shu, Y Hu… - 2019 - ascopubs.org
9089 Background: HER2 exon 20 mutation is a well-known oncogenic driver in non-small
cell lung cancer (NSCLC) and its testing is recommended by NCCN guidelines for NSCLC …
cell lung cancer (NSCLC) and its testing is recommended by NCCN guidelines for NSCLC …
MA04. 03 preliminary results of a phase II study about the efficacy and safety of pyrotinib in patients with HER2 mutant advanced NSCLC
S Ren, C Zhou, G Gao, C Su, X Chen, FY Wu, X Li… - Journal of Thoracic …, 2017 - jto.org
Background There is still an unmet need for targeted drugs in non-small cell lung cancer
(NSCLC) patients with HER2 mutation. Pyrotinib is an oral tyrosine kinase inhibitor targeting …
(NSCLC) patients with HER2 mutation. Pyrotinib is an oral tyrosine kinase inhibitor targeting …
[HTML][HTML] Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
S Mao, S Yang, X Liu, X Li, Q Wang, Y Zhang… - … Hematology & Oncology, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the
era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and …
era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and …
[HTML][HTML] Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label …
X Ai, Z Song, H Jian, Z Zhou, Z Chen, Y Yu, Z Li, S Lu - BMC cancer, 2021 - Springer
Background Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant
non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors …
non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors …
[HTML][HTML] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, J Jiang, Q Wang, S Yang… - Annals of …, 2019 - Elsevier
Background Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …
human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This …